Simcere’s Trilaciclib Wins NMPA Approval for Chemotherapy Myeloprotection
Jiangsu Simcere Pharmaceutical Co., Ltd’s trilaciclib has received marketing approval from the National Medical Products...
Jiangsu Simcere Pharmaceutical Co., Ltd’s trilaciclib has received marketing approval from the National Medical Products...
China’s National Health Commission (NHC) released the “Healthcare Statistical Communique 2021,” revealing increased healthcare spending,...
Sinopharm China National Biotec Group Co., Ltd (CNBG) announced a strategic partnership with the government...
China-based IVF specialist Suzhou Basecare Medical Co., Ltd (HKG: 2170) announced a strategic partnership with...
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its market filing for a biosimilar...
Shanghai-based gene editing firm CorrectSequence Therapeutics announced it has received a patent from the United...
Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) announced that the National Medical Products Administration (NMPA)...
Overland ADCT BioPharma (CY) Ltd, a joint venture between China’s Overland Pharmaceuticals and Switzerland’s ADC...
China-based Triastek Inc., a pharmaceutical 3D printing specialist, announced a partnership with US firm Eli...
China-based Zhejiang Medicine Co., Ltd (SHA: 600216) announced that its subsidiary NovoCodex Biopharmaceuticals Ltd has...
GenScript ProBio, a global Contract Development and Manufacturing Organization (CDMO), announced a memorandum of understanding...
Shanghai-based Abbisko Therapeutics Co., Ltd (HKG: 2256) announced that its Category 1 drug ABSK021 has...
China’s National Medical Products Administration (NMPA) announced that potassium glucosamine sulfate has been reclassified from...
China’s Joint Procurement Office (JPO) announced plans on July 11 to conduct a volume-based procurement...
China-based HutchMed (NASDAQ: HCM, HKG: 0013) announced the publication of an abstract detailing the SAVANNAH...
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) announced that the National Medical Products Administration (NMPA)...
Eli Lilly (NYSE: LLY) announced that its Phase III AWARD-CHN3 study of Trulicity (dulaglutide) combined...
China’s 7th national volume-based procurement (VBP) round concluded with winning bids averaging a 65.5% price...
The Center for Drug Evaluation (CDE) has granted priority review status to two drugs: Suzhou...
US-based Athenex Inc. (Nasdaq: ATNX) announced an agreement to sell all equity interests in its...